Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

A systematic review of the efficacy of CNS prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era.

Eyre TA, Djebbari F, Kirkwood AA, Collins GP.

Haematologica. 2019 Sep 5. pii: haematol.2019.229948. doi: 10.3324/haematol.2019.229948. [Epub ahead of print]

2.

A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.

Eyre TA, Hildyard C, Hamblin A, Ali AS, Houlton A, Hopkins L, Royston D, Linton KM, Pettitt A, Rule S, Cwynarski K, Barrington SF, Warbey V, Wrench D, Barrans S, Hirst CS, Panchal A, Roudier MP, Harrington EA, Davies A, Collins GP.

Hematol Oncol. 2019 Oct;37(4):352-359. doi: 10.1002/hon.2662. Epub 2019 Sep 9.

PMID:
31385336
3.

Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma.

Kesavan M, Eyre TA, Collins GP.

Curr Hematol Malig Rep. 2019 Aug;14(4):207-218. doi: 10.1007/s11899-019-00518-8. Review.

4.

Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.

Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez-Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR.

Br J Haematol. 2019 Oct;187(2):185-194. doi: 10.1111/bjh.16070. Epub 2019 Jun 20.

PMID:
31222719
5.

Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma.

Djebbari F, Browning JA, Stanton L, Booth S, Hildyard C, Willan J, Bosworth J, Vora SM, Hatton CSR, Collins GP, Eyre TA.

Br J Haematol. 2019 Sep;186(6):e191-e195. doi: 10.1111/bjh.16071. Epub 2019 Jun 20. No abstract available.

PMID:
31222716
6.

Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.

Suri A, Mould DR, Song G, Collins GP, Endres CJ, Gomez-Navarro J, Venkatakrishnan K.

Clin Pharmacol Ther. 2019 Dec;106(6):1268-1279. doi: 10.1002/cpt.1530. Epub 2019 Jul 9.

7.

Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.

Goswami P, Oliva EN, Ionova T, Else R, Kell J, Fielding AK, Jennings DM, Karakantza M, Al-Ismail S, Lyness J, Collins GP, McConnell S, Langton C, Al-Obaidi MJ, Oblak M, Salek S.

J Comp Eff Res. 2019 May;8(7):523-533. doi: 10.2217/cer-2018-0108. Epub 2019 Apr 30.

8.

Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.

Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields PA, Gunawan A, Oliver R, Booth S, McMillan A, Fox CP, Bishton M, Collins GP, Hatton CSR.

Br J Haematol. 2019 Aug;186(4):e94-e98. doi: 10.1111/bjh.15927. Epub 2019 Apr 24. No abstract available.

PMID:
31020646
9.

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.

Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, Fields P, Pocock C, Collins GP, Stephens R, Cucco F, Clipson A, Sha C, Tooze R, Care MA, Griffiths G, Du MQ, Westhead DR, Burton C, Johnson PWM.

Lancet Oncol. 2019 May;20(5):649-662. doi: 10.1016/S1470-2045(18)30935-5. Epub 2019 Apr 1.

10.

Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.

Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields P, Gunawan A, Oliver R, Djebbari F, Booth S, McMillan A, Fox CP, Bishton MJ, Collins GP, Hatton CSR.

J Intern Med. 2019 Jun;285(6):681-692. doi: 10.1111/joim.12889. Epub 2019 Apr 11.

PMID:
30811713
11.

Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.

Brierley CK, Jones FM, Hanlon K, Peniket AJ, Hatton C, Collins GP, Schuh A, Medd P, Clark A, Ward J, Chaganti S, Malladi R, Parker A, Craddock C, Danby R, Rocha V.

Br J Haematol. 2019 Feb;184(4):547-557. doi: 10.1111/bjh.15685. Epub 2018 Nov 22.

PMID:
30467838
12.

RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial.

Lim SH, Linton KM, Collins GP, Dhondt J, Caddy J, Rossiter L, Vadher K, Fines K, Rogers LE, Fernando D, Stanton L, Davies AJ, Johnson PWM, Griffiths G.

Trials. 2018 Nov 9;19(1):619. doi: 10.1186/s13063-018-2996-6.

13.

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM.

N Engl J Med. 2018 Nov 1;379(18):1711-1721. doi: 10.1056/NEJMoa1807315.

PMID:
30380386
14.

A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.

Eyre TA, Collins GP, Gupta A, Coupe N, Sheikh S, Whittaker J, Wang LM, Campo L, Soilleux E, Tysoe F, Cousins R, La Thangue N, Folkes LK, Stratford MRL, Kerr D, Middleton MR.

Cancer. 2019 Jan 1;125(1):99-108. doi: 10.1002/cncr.31791. Epub 2018 Oct 17.

15.

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.

Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, Hodson A, Coats J, Narat S, Morley N, Dyer MJS, Collins GP.

Haematologica. 2019 Feb;104(2):e68-e71. doi: 10.3324/haematol.2018.198812. Epub 2018 Sep 6. No abstract available.

16.

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE.

J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.

PMID:
29856692
17.

Seronegative antibody-mediated neurology after immune checkpoint inhibitors.

Wilson R, Menassa DA, Davies AJ, Michael S, Hester J, Kuker W, Collins GP, Cossins J, Beeson D, Steven N, Maddison P, Rinaldi S, Jacob S, Irani SR.

Ann Clin Transl Neurol. 2018 Mar 25;5(5):640-645. doi: 10.1002/acn3.547. eCollection 2018 May.

18.

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.

Gleeson M, Peckitt C, To YM, Edwards L, Oates J, Wotherspoon A, Attygalle AD, Zerizer I, Sharma B, Chua S, Begum R, Chau I, Johnson P, Ardeshna KM, Hawkes EA, Macheta MP, Collins GP, Radford J, Forbes A, Hart A, Montoto S, McKay P, Benstead K, Morley N, Kalakonda N, Hasan Y, Turner D, Cunningham D.

Lancet Haematol. 2018 May;5(5):e190-e200. doi: 10.1016/S2352-3026(18)30039-5.

19.

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM.

J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. Erratum in: J Clin Oncol. 2018 Sep 10;36(26):2748.

20.

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA.

J Clin Oncol. 2018 Apr 1;36(10):942-950. doi: 10.1200/JCO.2017.77.3994. Epub 2018 Feb 2.

21.

Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.

Collins GP, Rueda A, Salles G, von Tresckow B, Zaja F.

Leuk Lymphoma. 2018 Sep;59(9):2113-2120. doi: 10.1080/10428194.2017.1421762. Epub 2018 Jan 16.

PMID:
29334819
22.

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.

Ait-Tahar K, Anderson AP, Barnardo M, Collins GP, Hatton CSR, Banham AH, Pulford K.

Adv Hematol. 2017;2017:6527306. doi: 10.1155/2017/6527306. Epub 2017 Oct 24.

23.

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.

Eyre TA, Phillips EH, Linton KM, Arumainathan A, Kassam S, Gibb A, Allibone S, Radford J, Peggs K, Burton C, Stewart G, LeDieu R, Booth C, Osborne WL, Miall F, Eyre DW, Ardeshna KM, Collins GP.

Br J Haematol. 2017 Nov;179(3):471-479. doi: 10.1111/bjh.14898. Epub 2017 Aug 31. Erratum in: Br J Haematol. 2018 Jan;180(2):309.

PMID:
28857136
24.

Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma.

Hildyard C, Shiekh S, Browning J, Collins GP.

Clin Med Insights Blood Disord. 2017 Apr 24;10:1179545X17705863. doi: 10.1177/1179545X17705863. eCollection 2017.

25.

Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.

Eyre TA, Osborne WL, Gallop-Evans E, Ardeshna KM, Kassam S, Sadullah S, Sidra G, Culligan D, Arumainathan A, Shankara P, Bowles KM, Eyre DW, Peng YY, Pettengell R, Bloor A, Vandenberghe E, Collins GP.

Br J Haematol. 2018 May;181(4):555-559. doi: 10.1111/bjh.14665. Epub 2017 Mar 24. No abstract available.

PMID:
28342183
26.

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R.

Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6.

27.

Cumulative burden of disease: a relevant measure of the late side-effects of cancer treatment.

Aznar MC, Darby S, Collins GP, Cutter D.

Lancet Oncol. 2016 Sep;17(9):1189-90. doi: 10.1016/S1470-2045(16)30283-2. Epub 2016 Jul 25. No abstract available.

PMID:
27470082
28.

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.

Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S, Follows G, Fox CP, Gribben J, Hillmen P, Hatton CS, Littlewood TJ, McCarthy H, Murray J, Pettitt AR, Soilleux E, Stamatopoulos B, Love SB, Wotherspoon A, Schuh A.

Br J Haematol. 2016 Oct;175(1):43-54. doi: 10.1111/bjh.14177. Epub 2016 Jul 5.

PMID:
27378086
29.

Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.

Eyre TA, Linton KM, Rohman P, Kothari J, Cwynarski K, Ardeshna K, Bailey C, Osborne WL, Rowntree C, Eden D, Shankara P, Eyre DW, Jasani P, Chaidos A, Collins GP, Hatton CS.

Br J Haematol. 2016 Jun;173(6):896-904. doi: 10.1111/bjh.14021. Epub 2016 Mar 9.

PMID:
26956150
30.

Acute EBV masquerading as peripheral T-cell lymphoma.

Zhang XY, Collins GP, Soilleux E, Eyre TA.

BMJ Case Rep. 2016 Feb 2;2016. pii: bcr2015213573. doi: 10.1136/bcr-2015-213573.

31.

Science and Culture: Kirigami and technology cut a fine figure, together.

Collins GP.

Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):240-1. doi: 10.1073/pnas.1523311113. No abstract available.

32.

Focal segmental glomerulosclerosis in a patient with mantle cell lymphoma.

Hindocha S, Gopaluni S, Collins GP, Shenbagaraman P.

BMJ Case Rep. 2015 Sep 9;2015. pii: bcr2015211765. doi: 10.1136/bcr-2015-211765.

33.

Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma.

Eyre TA, Salisbury R, Eyre DW, Watson C, Collins GP, Hatton CS.

Br J Haematol. 2016 May;173(3):487-91. doi: 10.1111/bjh.13619. Epub 2015 Jul 29. No abstract available.

PMID:
26223361
34.

Immune checkpoint inhibition in lymphoid disease.

Eyre TA, Collins GP.

Br J Haematol. 2015 Aug;170(3):291-304. doi: 10.1111/bjh.13397. Epub 2015 Mar 30. Review.

PMID:
25824455
35.

A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.

Collins GP, Eyre TA, Linton KM, Radford J, Vallance GD, Soilleux E, Hatton C.

Br J Haematol. 2015 Sep;170(6):886-90. doi: 10.1111/bjh.13333. Epub 2015 Feb 26. No abstract available.

PMID:
25721307
36.

Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience.

Eyre TA, Gatter K, Collins GP, Hall GW, Watson C, Hatton CS.

Am J Hematol. 2015 Jun;90(6):E103-10. doi: 10.1002/ajh.23989. Epub 2015 May 4.

37.

Management and controversies of classical Hodgkin lymphoma in pregnancy.

Eyre TA, Lau IJ, Mackillop L, Collins GP.

Br J Haematol. 2015 Jun;169(5):613-30. doi: 10.1111/bjh.13327. Epub 2015 Feb 13. Review.

PMID:
25684034
38.

A rare but potentially fatal cause of diarrhoea and weight loss: enteropathy-associated T-cell lymphoma.

Wali GN, Tyrrell HE, Collins GP, Eagleton HJ.

BMJ Case Rep. 2015 Jan 7;2015. pii: bcr2014204125. doi: 10.1136/bcr-2014-204125.

39.

Identification of a novel mutation in MAGT1 and progressive multifocal leucoencephalopathy in a 58-year-old man with XMEN disease.

Dhalla F, Murray S, Sadler R, Chaigne-Delalande B, Sadaoka T, Soilleux E, Uzel G, Miller J, Collins GP, Hatton CS, Bhole M, Ferry B, Chapel HM, Cohen JI, Patel SY.

J Clin Immunol. 2015 Feb;35(2):112-8. doi: 10.1007/s10875-014-0116-2. Epub 2014 Dec 13. Review.

40.

Long-term outcomes of autologous stem cell transplantation for peripheral T-cell lymphomas across the Thames Valley (1997-2012).

Sims MC, Newell K, Eyre TA, Hatton C, Collins GP.

Br J Haematol. 2015 May;169(3):452-5. doi: 10.1111/bjh.13226. Epub 2014 Nov 16. No abstract available.

PMID:
25399667
41.

A 72-year-old woman with a persistent cough and abnormal chest X-ray.

Corcoran JP, Moore AJ, Ho LP, Davies SJ, Collins GP.

Br J Hosp Med (Lond). 2014 Nov;75(11):652-3. doi: 10.12968/hmed.2014.75.11.652. No abstract available.

PMID:
25383438
42.

Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.

Eyre TA, Collins GP, Goldstone AH, Cwynarski K.

Br J Haematol. 2014 Aug;166(3):336-51. doi: 10.1111/bjh.12945. Epub 2014 May 19. Review.

PMID:
24842496
43.

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.

Eyre TA, Khan D, Hall GW, Collins GP.

Eur J Haematol. 2014 Dec;93(6):455-68. doi: 10.1111/ejh.12360. Epub 2014 May 21. Review.

PMID:
24766435
44.

Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.

Rule S, Collins GP, Samanta K.

J Med Econ. 2014 Jul;17(7):459-68. doi: 10.3111/13696998.2014.914033. Epub 2014 May 7.

PMID:
24720836
45.

Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect.

Eyre TA, Gooding S, Patel I, Moore N, Hatton C, Collins GP.

Int J Hematol. 2014 Jun;99(6):798-800. doi: 10.1007/s12185-014-1555-5. Epub 2014 Mar 2.

PMID:
24584910
46.

T-cell/histiocyte-rich large B-cell lymphoma--transformation of nodular lymphocyte predominant Hodgkin lymphoma in the bone marrow.

Eyre TA, King AJ, Hatton C, Collins GP.

Eur J Haematol. 2014 Jun;92(6):550-1. doi: 10.1111/ejh.12278. Epub 2014 Feb 21. No abstract available.

PMID:
24483596
47.

Classical Hodgkin's lymphoma: past, present and future perspectives.

Eyre TA, King AJ, Collins GP.

Br J Hosp Med (Lond). 2013 Nov;74(11):612-8. Review. No abstract available.

PMID:
24220522
48.

Current treatment and future prospects for peripheral T-cell lymphoma.

Eyre TA, Collins GP.

Drugs Today (Barc). 2013 Oct;49(10):631-46. doi: 10.1358/dot.2013.49.10.2025391. Review.

PMID:
24191256
49.

Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest.

Eyre TA, King AJ, Peniket A, Rocha V, Collins GP, Pawson R.

Transfusion. 2014 May;54(5):1231-4. doi: 10.1111/trf.12429. Epub 2013 Sep 30.

PMID:
24117899
50.

Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma.

Collins GP, Parker AN, Pocock C, Kayani I, Sureda A, Illidge T, Ardeshna K, Linch DC, Peggs KS; British Committee for Standards in Haematology; British Society of Blood and Marrow Transplantation.

Br J Haematol. 2014 Jan;164(1):39-52. doi: 10.1111/bjh.12582. Epub 2013 Oct 1. No abstract available.

PMID:
24117159

Supplemental Content

Loading ...
Support Center